BioSpecifics Technologies Balance Sheet - Annual (NASDAQ:BSTC)

Add to My Stocks
$58.17 $0.06 (0.1%) BSTC stock closing price Sep 19, 2018 (Closing)

The financial analysis of a company involves interpreting the income statement, balance sheet and cash flow statements of the company to draw insights like we've done in our BioSpecifics Technologies stock analysis. Balance sheet items like cash at hand, total assets and liabilities helps one analyze a company and summarize the financial performance of the company like we have in our BioSpecifics Technologies stock analysis. Annual results are typically accompanied with the company releasing financial statements. The BioSpecifics Technologies balance sheet for 2017 shows total assets of $74.99M. The company has a asset turnover ratio of 0.32. Also see: BioSpecifics Technologies revenue and BioSpecifics Technologies operating cash flow for the same year.

View latest 10 year balance sheet data to check BioSpecifics Technologies financial performance.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Marketable Securities51.97M44.25M28.34M10.9M6.96M5.12M5M5.36M4.54M-
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets2.41M2.07M1.41M---1.4M---
Total Current Assets
Property Plant & Equipment----1.83M1.83M1.83M1.83M1.83M1.83M
Accumulated Depreciation----1.83M1.83M1.83M1.83M1.83M1.83M
Net Property Plant & Equipment
Investment & Advances5.74M3.77M3.59M1.25M------
Other Non-Current Assets----------
Deferred Charges2.47M5.26M3.45M4.33M4.76M4.23M2.98M1.25M1.25M1.25M
Deposits & Other Assets----------
Total Assets
Notes Payable----------
Accounts Payable----------
Current Portion Long-Term Debt----------
Current Portion Capital Leases----------
Accrued Expenses-------2.64M2.96M-
Income Taxes Payable----------
Other Current Liabilities1.13M1.25M-------1.27M
Total Current Liabilities
Deferred Taxes/Income5.34M6.41M------1.15M1.9M
Convertible Debt----------
Long-Term Debt----------
Non-Current Capital Leases----------
Other Long-Term Liabilities---------2.75M
Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus33.46M32.94M31.79M25.05M20.95M20.68M20.04M17.73M15.16M13.29M
Retained Earnings41.93M30.61M19.23M9.62M4.97M-0.31M-3.29M-9.89M-8.38M-6.42M
Treasury Stock7.89M7.28M6.23M4.43M3.6M2.92M1.89M1.15M--
Other Liabilities----------
Shareholders Equity67.51M56.28M44.81M30.25M22.33M17.45M14.87M6.7M6.09M6.17M
Total Liabilities & Shareholders Equity74.99M64.69M45.69M31.02M23.25M18.39M16.26M11.51M11.74M12.83M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Apart from balance sheet items, an investor would do well to keep track of the BioSpecifics Technologies stock price by looking at BioSpecifics Technologies historical stock prices. One can compare PE with industry average by looking at the BioSpecifics Technologies PE ratio chart. The common balance sheet items are:

  • Assets: Anything that the BioSpecifics Technologies company owns and is a part of its books. Assets can be of three types: fixed, current and other assets which includes intangibles, advances. Internet companies typically don't have a lot of assets as there is not much investment in say machinery, equipment etc. BioSpecifics Technologies had total assets of $74.99M.
  • Liabilities: The total liabilities of BioSpecifics Technologies for the year 2017 total to $7.47M. Liabilities for a company like BioSpecifics Technologies include bank loans, services which have been availed for which a settlement in the form of cash/ asset transfer needs to be done in future etc. A firm takes on such obligations to grow its business which in turn will generate future economic benefits for its business.

BioSpecifics Technologies Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover
Price to book ratio

Annual Balance Sheets For BioSpecifics Technologies Corp. Peers

Auxilium Pharma balance sheet, Dermira balance sheet, Lipocine balance sheet, NephroGenex balance sheet